Ahvaz Jundishapur University of Medical Sciences   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Ahwaz Iran (Islamic Republic of) (1955)

Organization Overview

First Clinical Trial
2008
NCT01348321
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Ahvaz Jundishapur University of Medical Sciences | Ahvaz University of Medical Sceinces, Ahvaz, Iran

Active Ingredients

Drugs in Phase 4 Trials (2)

daclatasvir (daklinza) (1 trial)

sofosbuvir (sovaldi) (1 trial)

Drugs in Phase 3 Trials (3)

fludrocortisone (florinef) (1 trial)

levamisole (ergamisol) (1 trial)

midodrine (proamatine) (1 trial)

Drugs in Phase 2 Trials (1)

l-epigallocatechin (1 trial)

Drugs in Phase 1 Trials (1)

vitamin d3 (1 trial)

Drugs in Other Trials (2)

pomegranate (1 trial)

soybean (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

Irritable Bowel Syndrome (Phase 1)

Kidney Failure, Chronic (Phase 4)

Lupus Erythematosus, Systemic (Phase 2)

Renal Insufficiency (Phase 4)

Syncope (Phase 3)

Syncope, Vasovagal (Phase 3)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 9